Wockhardt Ltd
Wockhardt Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Wockhardt aims to double its business in the next 3 years, driven by increased capacity and growing demand, especially in novel antibiotics and biosimilars. EBITDA growth: Recorded a 67% increase in the last year, with EBITDA margins expanding by 500 basis points from 9% to 14%.
From Wockhardt Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Wockhardt aims to double its business in the next 3 years, driven by increased capacity and growing demand, especially in novel antibiotics and biosimilars.
- The novel antibiotic ZAYNICH targets a global addressable market of about $9 billion with plans to scale in India and Western markets, including the US and Europe.
- Miqnaf targets the Indian respiratory antibiotic market valued at INR10,800 crores with specialist-focused promotion over the next 3-4 years.
- The diabetes biosimilar business, particularly insulin glargine and other analogs, represents a significant growth area in emerging markets and India, with new product launches planned.
2 more points from Wockhardt Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Wockhardt Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Wockhardt is doubling its insulin and biotech manufacturing capacity over the next 24 to 36 months to meet growing demand and capitalize on emerging market opportunities.
- The company is setting up a new facility for biotech products to support expansion in insulin analogs and related drugs.
- Continued investment in R&D is planned, with an ongoing spend of around USD 200-250 million annually on new drug discovery and development, including antibiotics and biosimilars.
2 more points from Wockhardt Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Wockhardt Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Wockhardt Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Wockhardt Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹965 Cr, net profit ₹164 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Wockhardt Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharma. (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Arthneeti Pro · Annual
Wockhardt Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Wockhardt Ltd Q4 FY25 results?
Wockhardt aims to double its business in the next 3 years, driven by increased capacity and growing demand, especially in novel antibiotics and biosimilars. EBITDA growth: Recorded a 67% increase in the last year, with EBITDA margins expanding by 500 basis points from 9% to 14%.
What is Wockhardt Ltd share price analysis?
Wockhardt Ltd currently shows a neutral. The stock trades at a P/E of 114.8 with a market cap of ₹32,598 Cr. Investors should review the full earnings analysis for detailed insights.
Is Wockhardt Ltd planning capital expenditure?
Wockhardt is doubling its insulin and biotech manufacturing capacity over the next 24 to 36 months to meet growing demand and capitalize on emerging market opportunities.
Keep Wockhardt Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.